Icon

HETLIOZ LQ (nda214517)- (4MG/ML,4MG/ML)

TASIMELTEON VANDA PHARMS INC
4MG/ML,4MG/ML
Yes No
2041-Feb-21 Expired
None 2023-Dec-01
None No
HETLIOZ is a melatonin receptor agonist. HETLIOZ LQ oral suspension is indicated for the treatment of: • Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age.
0 0 0
Total Other Developers None
Drugs with Suitability No
4MG/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.